Credit Agricole S A Sells 116,477 Shares of Humana Inc. $HUM

Key Points

• Credit Agricole S A has significantly reduced its stake in Humana Inc. by 68.0%, selling 116,477 shares and now owning 54,901 shares valued at approximately $14.5 million.
• Several institutional investors have increased their stakes in Humana, with notable increases from BNP PARIBAS ASSET MANAGEMENT (+61.5%) and Quantbot Technologies (+1,453%) during the first quarter.
• Analysts have varied price targets for Humana, with Oppenheimer raising its target to $310 while others like Piper Sandler lowered it to $272, indicating mixed expectations for the stock's performance.

Credit Agricole S A lowered its stake in Humana Inc. (NYSE:HUM - Free Report) by 68.0% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 54,901 shares of the insurance provider's stock after selling 116,477 shares during the quarter. Credit Agricole S A's holdings in Humana were worth $14,527,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Deutsche Bank AG boosted its stake in shares of Humana by 18.2% during the 4th quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after acquiring an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Humana during the 1st quarter worth $1,309,000. Fred Alger Management LLC purchased a new position in shares of Humana during the 4th quarter worth $451,000. Clearline Capital LP purchased a new position in shares of Humana during the 4th quarter worth $1,102,000. Finally, Envestnet Asset Management Inc. boosted its stake in shares of Humana by 2.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider's stock worth $33,256,000 after acquiring an additional 2,950 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Price Performance

NYSE HUM traded up $0.75 on Tuesday, reaching $297.95. The company had a trading volume of 270,931 shares, compared to its average volume of 1,713,182. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $35.83 billion, a PE ratio of 22.85, a price-to-earnings-growth ratio of 1.76 and a beta of 0.44. The firm's 50 day moving average price is $249.83 and its 200 day moving average price is $253.46. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $382.72.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The company had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The business's revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. As a group, equities analysts predict that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a $0.885 dividend. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana's payout ratio is 27.17%.

Wall Street Analyst Weigh In

HUM has been the topic of several analyst reports. Royal Bank Of Canada lifted their price target on shares of Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Piper Sandler dropped their price target on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research note on Thursday, July 31st. Oppenheimer lifted their target price on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Truist Financial lowered their target price on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a research note on Wednesday, July 16th. Finally, Robert W. Baird lowered their target price on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Seven analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the stock. According to MarketBeat.com, Humana currently has a consensus rating of "Hold" and an average target price of $283.29.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.